Ra Pharmaceuticals Inc

Ra Pharma was incorporated in Delaware in 2008 and is headquartered in Cambridge, Massachusetts. This clinical-stage biopharmaceutical company is focused on leading the field of complement biology. The company’s technology can replace injectable biologics for a range of common and rare diseases. Ra Pharma uses its Extreme Diversity™proprietary peptide and small molecule chemistry platform to develop treatment of serious, rare diseases caused by excessive or uncontrolled activation of the complement system, which is a critical component of the immune system. The company was able to develop a portfolio of products, including its lead program, Zilucoplan. In October 2019, Ra Pharma announced the entry into a merger agreement after which it was to be acquired by UCB. The transaction is expected to close by the end of the first quarter of 2020. The company’s financial highlights for the third quarter of fiscal 2019 included reported $3 million of revenue related to a payment for the achievement of a clinical development milestone under the company’s collaboration agreement with Merck. Track this instrument for more updates and news on the current RARX value.